Randomised phase III study of gemcitabine, cisplatin plus S-1 (GCS) compared with gemcitabine plus cisplatin (GC) for unresectable or recurrent biliary tract cancer (KHBO1401-MITSUBA).
Tatsuya Ioka(National Cancer Center Hospital East), Jiro Fujimoto(Harvard University), Shogo Kobayashi(Osaka Gakuin University), Masashi Kanai(Kyoto University Hospital), Takuma Goto(Asahikawa Medical University), Daisuke Sakai(Stowers Institute for Medical Research), Kenichi Yoshimura(Hiroshima University), Etsuro Hatano(Kyoto University), Naoko Chayahara(Kobe University Hospital), Masahiro Murakami(Purdue University West Lafayette), Hiroki Yamaue(Wakayama Medical University), Hideyuki Hayashi(Hokkaido University Hospital), Amane Kitasato(Nagasaki University), Keiko Kamei(Kindai University Sakai Hospital), Masahiro Takahashi(Tohoku University Hospital), Takatsugu Yamada(Nara Medical University)
Cited by 1
Related Papers
Constitutive activation of the 41-/43-kDa mitogen-activated protein kinase signaling pathway in human tumors
|Oncogene|1999|693
Randomized Phase III Study of Gemcitabine Plus S-1, S-1 Alone, or Gemcitabine Alone in Patients With Locally Advanced and Metastatic Pancreatic Cancer in Japan and Taiwan: GEST Study
|Journal of Clinical Oncology|2013|632
Hepatocyte growth factor gene therapy of liver cirrhosis in rats
|Nature Medicine|1999|588